Skip to content

Artiva Biotherapeutics, Inc. ARTV Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Gilead Sciences logo
Gilead SciencesGILD
Allogene Therapeutics logo
Allogene TherapeuticsALLO
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
Avalo Therapeutics logo
Avalo TherapeuticsAVTX

Other financials

Income statement

See full
Revenue-
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-67.9%
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s common stock, shares authorized (in shares)?
Artiva Biotherapeutics, Inc. (ARTV) reported common stock, shares authorized (in shares) of $700M in Q3 2024.